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Abstract
Background: De novo heterozygous mutations in the GNAO1 gene, encoding the Gα o subunit of G-proteins, are
the cause of a severe neurodevelopmental disorder, featuring early infantile seizures, profound cognitive dysfunction
and, occasionally, movement disorder (early infantile epileptic encephalopathy-17).
Methods: We report a further case of this association in a 20 month-old Spanish girl with neonatal-onset refractory
seizures, progressive microcephaly, oral-lingual dyskinesia and nearly absent psychomotor development. We performed
whole-exome sequencing, a computational structural analysis of the novel gene variant identified and reviewed the
previously reported cases.
Results: Trio whole-exome-sequencing uncovered a de novo p.Leu199Pro GNAO1 mutation. Computational structural
analysis indicates this novel variant adversely affects the stability of the G-protein heterotrimeric complex as a whole.
Of note, our patient showed a sustained seizure reduction while on a ketogenic diet.
Conclusions: With this observation, a total of twelve patients with GNAO1 encephalopathy have been reported.
Oral-lingual dyskinesia and responsiveness of seizures to ketogenic diet are novel features. The distorted sex ratio (12/
12 females) of the condition remains unexplained; a differential gender effect of the disruption of G-protein- mediated
signal transduction on the developing brain can be hypothesized.
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Background
Epileptic encephalopathy is a group of neurological disor-
ders characterized by severe and progressive cognitive and
behavioral impairments, which are most probably caused
or worsened by epileptic activity [1]. Heterozygous muta-
tions in the GNAO1 gene (MIM*139311), encoding the
alpha subunit of the heterotrimeric guanine nucleotide-
binding proteins (G proteins), were first described as a
cause of early infantile epileptic encephalopathy (EIEE) in
2013 [2]. Subsequent reports have broadened the
spectrum of clinical presentation [3–5] which includes
prominent dyskinesia and intellectual disability with few
or no seizures (4) and the condition is currently classified
as EIEE17 (MIM #615473). Interestingly, all the cases re-
ported to date involve female subjects despite the disease-
causing gene maps to chromosome 16q13.
The GNAO1 gene product is the alpha subunit of Go,
a member of the G-protein family, involved in cellular
signal transduction. Three functional G-protein subtypes
are defined, namely inhibitory G-proteins (Gi), stimula-
tory G-proteins (Gs) and “other” (Go) the latter being
abundantly expressed in the brain [6]. Typically, G-
proteins are characterized by their alpha subunit, which
binds and hydrolyzes GTP and interacts with specific
GPCRs (G-protein coupled receptors) or effector mole-
cules, such as adenylate cyclase. Relevant to neuronal
excitability, Go proteins modulate neurotransmitter re-
lease by mediating the presynaptic auto-inhibitory effect
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of several neurotransmitters on their receptors, includ-
ing M2/M4 muscarinic, alpha(2) adrenergic, mu/delta
opioid and GABA-B receptors [7].
We here report the first Spanish girl with this disorder
carrying a de novo GNAO1 heterozygous mutation.
State-of-the-art computational analyses suggest that this




The patient is a 21 month-old girl with a severe encephal-
opathy presenting with neonatal seizures. She is the second
child of unrelated, healthy parents. A 4 year-old sister is
healthy. Pregnancy and delivery were uneventful. Neonatal
physical examination was reportedly normal, with head cir-
cumference of 34 cm (35th percentile). Seizures appeared
on the third day of life and were tonic generalized or mani-
fested as facial congestion, drooling, or motor phenomena
such as sucking, grimacing or winking. They lasted from
seconds to a few minutes, recurred up to 40 times per day
and were refractory to treatment, including a pyridoxal
phosphate-containing vitamin cocktail.
She was referred for study at the age of 3 months. The
physical examination revealed a head growth deceleration
(head circumference at 38,8 cm, 3rd percentile), low-set
ears without other dysmorphic features, drowsiness with
lack of visual fixation when awake, decreased muscle tone,
reduced spontaneous movements and occasional startle.
Interictal EEG recordings showed diffuse background
slowing, and multifocal high-voltaged sharp waves and
spike and slow-wave complexes, with predominance over
both central-parietal areas. An extensive metabolic
workup, including CSF lactate, amino acids and neuro-
transmitter metabolites, array CGH, fundoscopic examin-
ation and visual evoked potentials were normal. A
previous brain MRI study, performed at 18 days of life,
showed signs consistent with mild cerebral atrophy, thin
corpus callosum and delayed myelination (Fig. 1).
On follow-up, EEG’s continued to show a slowed and
high-voltaged background activity with poor differenti-
ation and absent sleep elements plus very abundant, al-
most constant, bilateral sharp wave elements, consistent
with severe epileptic encephalopathy. Seizures persisted
unchanged despite the use of multiple antiepileptic
drugs, including phenobarbital, valproate, levetiracetam,
vigabatrin, carbamazepine, zonisamide, clobazam, topira-
mate and lacosamide in different combinations as well
as a short trial with hydroaltesone. Although a slight im-
provement in seizure frequency was eventually obtained
with a carbamazepine, topiramate and clobazam at age
11 months she was still suffering 15–20 seizures per day,
mostly tonic generalized with upgaze deviation. With
the institution of a 1:3 ketogenic diet (KD) seizure
frequency progressively diminished and she remained
seizure-free for almost two months. However, non-
compliance with the KD resulted in recurrence of
seizures. She currently averages 1–4 seizures per day. At
age 19 months an EEG performed during sleep captured
two seizures with, respectively, right and left mesial
frontal origin. At age 21 months, the patient is severely
disabled; she has not attained cephalic control or visual
fixation and does not respond to any social cues. On
examination, head circumference is 43 cm (<−3SD),
height 86 cm (33th percentile) and weight 14 Kg (96th
percentile). There is severe axial hypotonia, spastic
Fig. 1 Brain MRI at age 18 days. Sagittal T1WI view showing thinning of the corpus callosum (arrow), with anterior predominance, and some
degree of frontal lobe volume reduction (a). Axial T2WI view showing asymmetric enlargement of temporal subarachnoidal spaces (arrow) and
mildly prominent sulci over the cerebral convexity, suggesting incipient atrophy. Myelination is delayed with minimal signals observed at the
posterior limb of the internal capsule (arrowhead) and corpus callosum (b)
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tetraparesis, brisk deep tendon reflexes and paucity of vol-
untary movements. She has recently begun to display dys-
kinetic buccolingual movements, but without evidence of
adventitious movements involving the trunk or limbs.
Genetic studies and whole-exome sequencing
Peripheral blood samples were collected from the trio
(patient and both progenitors). Genomic DNA was iso-
lated using a standard salting-out method. The study
was approved by the Vall d'Hebron University Hospital
Institutional Review Board and informed consent was
obtained from the patient’s parents according to the
Helsinki declaration.
Exome sequencing of DNA samples from the trio
was performed at the Centre Nacional d’Anàlisi Genò-
mica (CNAG) in Barcelona. 1 μg of genomic DNA
was fragmented with an ultra sound device (Covaris,
Woburn, MA, USA), denatured and hybridized with
capture oligos (NimbleGen SeqCap EZ Exome v3.0
exome enrichment kit, Roche, Madison, WI, USA)
which enriches for ~44 Mb of the human exonic
regions. Captured sequences were enriched with
streptavidin-conjugated paramagnetic beads. End re-
pair, A-tailing, Illumina adapter ligation and post-
capture amplification were done with TruSeq PE
Cluster Kit v3, Illumina Corp, La Jolla, CA). Each
captured exome was sequenced in one HiSeq2000
lane using version 3 chemistry. Coverage over 30X -was
achieved for more than 80 % of the target. Alignment and
variant calling were carried out following the GATK best
practices for whole-exome sequencing. Sequencing reads
were aligned to b37-decoy reference using BWA (http://
bio-bwa.sourceforge.net/), then we marked duplicates,
performed local realignment around indels, recalibrated
the base quality scores, called variants with Haploty-
peCaller and filtered them using Variant Quality
Score Recalibration (VQSR) and hard filters. Refine-
ment was done considering the pedigree, the popula-
tion frequencies from Exome aggregation consortium
(http://exac.broadinstitute.org/) [8], NHLBI Exome
Sequencig Project (http://evs.gs.washington.edu/EVS/) [9],
1000 genomes project (http://www.1000genomes.org/)
[10] and dbsnp (http://www.ncbi.nlm.nih.gov/SNP/) [11]
and finally, the functional annotation (SnpEff, SnpSift) and
the disease. In a first tier analysis (diagnostic exome se-
quencing) we investigated any variants within genes previ-
ously associated with epilepsy. This was followed by
consideration of variants in any other gene covered by
WES (research exome sequencing). Both, de novo muta-
tions and transmitted alleles were analyzed. All candidate
selected de novo mutations were absent in ExAC, and
passed visual inspection of alignment quality using the
Integrative Genomics Viewer (IGV).
Sanger sequencing was performed to confirm the
GNAO1 de novo missense variant identified through
whole-exome sequencing. To that end, exon six from the
proband and progenitors was amplified by Polymerase-
Chain-Reaction (PCR), purified and sequenced using the
BigDye Terminator cycle sequencing kit v3.1 and an auto-
mated sequencer ABI PRISM 3730 DNA Analyzer (Applied
Biosystems, Foster City, CA, USA) (primer sequences and
PCR conditions available upon request).
Structural modeling and free-energy calculations
Homology modeling human Gαo protein
The human WT Gαo protein was homology modeled
from the crystal structure of mouse Gαo (PDB id: 3C7K)
with MODELLER [12] (residues 22–346, see Additional
file 1: Table S1 for sequence alignment). The sequence
identity between mouse and human protein is 98 %.
During homology modeling, conserved residues were
maintained in their original crystal structure rotameric
orientation. The co-crystallized ligands GDP and MG
were directly transferred from the crystal structure into
the homology model. The WT homology model was
energy-minimized in the AMBER14SB force-field [13]
with 1000 steps of steepest descent and 100 steps of
conjugate gradients in CHIMERA [14]. The p.Leu199Pro
mutation was inserted into the WT homology model
with CHIMERA by applying the most appropriate side-
chain rotamer and then energy-minimizing the mutant
protein as performed previously in the AMBER14SB
force-field.
Calculation of free-energy change
The predicted free-energy change (ddG) of the
p.Leu199Pro mutation in human Gαo was made using
ROSETTA [15] with a conversion factor of 0.73
employed to convert Rosetta Energy Units to kcal/mol
[16]. The program was executed in “high-resolution
mode” with full protein flexibility in side-chains and
backbone (without bound GDP) and with the following
flags: “iterations” set to 50, “local_opt_only” set to false,
“sc_min_only” set to false, “opt_radius” set to 12.0, and
“fa_max_dis” set to 9.0.
Molecular dynamics simulations
Both Gαo WT and Gαo Leu199Pro molecular dynamics
(MD) systems were built using Amber LEap from
AmberTools14 [13]. Ions were added to neutralize both
systems and salt was added at a concentration of 0.2 M
in each. Each system was then equilibrated with MD
using ACEMD (Accelerating Biomolecular Dynamics in
the Microsecond Time Scale) [17] at 300° and a pressure
of 1 atm (NPT) in the AMBER14SB force-field for a
total of 7.0 ns with harmonic restraints on the protein
progressively relaxed from 10 kcal mol−1 Å−2 to
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0 kcal mol−1 Å−2. Production run MD simulations of
1000 ns were then performed for both WT and mutant
Leu199Pro proteins at 300° (NVT) in the AMBER14SB
force-field using ACEMD [17]. VMD 1.9.2 [18] was used
for RMSD (root-mean-square deviation) analyses of MD
simulations, including heat-map generation.
Results
Whole-exome sequencing
Whole exome sequencing from the patient and her par-
ents (trio-based variant analysis) identified a single de
novo variant within the epilepsy candidate genes, a het-
erozygous mutation GRCh37/hg19:chr16:56370645,
NM_020988.2: c.596 T > C in GNAO1, producing the
amino acid change p.Leu199Pro (NP_066268.1) in the
proband. Read depth at the variant position was 38X,
42X and 50X for the proband and progenitors, respect-
ively. The mutation was confirmed by PCR and Sanger
sequencing (Fig. 2). This variant has not been previously
described as related to the phenotype and is not present
in any of the public genomic databases listed above. In
silico prediction sofwares (SIFT [19], Mutation Taster
[20] andPolyPhen-2 [21]) classified the novel variant as
damaging. Despite the location of the variant in close
proximity to a splice junction, the ESEfinder [22, 23]
and Netgene2 [24, 25] scores did not indicate an effect
on splicing (data not shown).
Computational structural analysis
The human WT Gαo protein with bound GDP was
homology modeled from the crystal structure of mouse
Gαo (PDB id: 3C7K) using MODELLER [8]. As these
proteins share 98 % sequence identity, homology model-
ing accuracy can be considered very high (see Methods
for details and Supplementary Information). The
Leu199Pro mutation was introduced with CHIMERA
[14]. The Leu199Pro mutation site is located in the
GTPase domain of Gαo, specifically residing in the
interior of a β-sheet that is packed between the N- and C-
termini and interacting with adjacent α-helices. According
to the homology model of human Gαo, Leu199 is not
involved in GDP/GTP binding so its mutation to proline
is not predicted to directly affect ligand binding or
hydrolysis (see Fig. 3a).
The WT and mutant forms of human Gαo were ana-
lysed with ROSETTA [15] to calculate the predicted
Fig. 2 a Left, pedigree of the affected patient, showing the carrier of the heterozygous of the de novo mutation (filled symbol) and her unaffected
sister and parents. Right, validation of the identified mutation by means of PCR and Sanger sequencing: electropherograms show the
wild-type sequence in the progenitors (top) and the novel GNAO1 c.596 T > C (NM_020988.2) variant in the proband (bottom), producing
the amino acid change p.Leu199Pro (NP_066268.1). b Multiple sequence alignment of the GNAO1 protein region containing Leucine 199
(NP_066268.1) illustrating the high degree of evolutionary conservation of the affected residue
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free-energy change (ddG) of the mutation. Using a con-
version factor of 0.73 to convert from Rosetta Energy
Units to kcal/mol [12], the predicted ddG of Leu199Pro
is +6.1 kcal/mol. This suggests the mutation has a desta-
bilizing effect on the protein and could possibly cause
defects in its folding. To investigate this effect in more
detail, both the WT protein and Leu199Pro mutant were
subjected to a 1 μ-second MD simulation using ACEMD
[13]. During these simulations, the WT protein remains
stable in terms of both its secondary and tertiary struc-
ture with an RMSD that fluctuates between 1.0 and
2.0 Å (Fig. 3d). However the Leu199Pro mutant displays
significant structural change in its GTPase domain, with
multiple H-bonding in its central B-sheet broken, causing
the creation of a large flexible loop region and increased
positional fluctuation (Fig. 3c), with a protein RMSD of
1.5–3.0 Å across the simulation (Fig. 3d). In addition, the
mutation also affects other areas of the domain, in par-
ticular α-helices: 208–217 and 257–262, both which lose
their structural integrity and experience greater positional
fluctuation during the simulation (Fig. 3c).
In the context of the protein as a whole, heat-map rep-
resentations of positional fluctuation reveal structural dis-
turbances across both domains, GTPase and helical, in the
mutant Leu199Pro protein (see Fig. 4). These disturbances
occur in areas already described in the GTPase domain
but also in several loop regions throughout the protein.
Discussion
Early infantile epileptic encephalopathy-17 is a severe
neurological disorder characterized by onset of intract-
able seizures in the first weeks or months of life, usually
Fig. 3 a Homology model of human WT Gαo. The mutated Leu199 is highlighted in yellow space-fill, protein backbone with secondary structure
in beige, GDP in red/orange space-fill, magnesium in green. b Structural superposition of mutant Leu199Pro Gαo protein after 1 μ-second of MD
simulation (in pink with mutation Leu199Pro shown as red space-fill) and heterotrimeric guanine-nucleotide-binding protein Gi (PDB id: 1GG2, Giα in
beige, Giβ in cyan, Giγ in green). c GTPase domain of mutant Leu199Pro Gαo (in pink) compared to WT (in green) after 1 μ-second MD simulations
(mutation Leu199Pro shown in red space-fill). d Plot of RMSD (a) for Cα atoms of WT Gαo protein and Leu199pro mutant during 1 μ-second MD simu-
lations (RMSD comparisons made against initial structure)
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associated with EEG abnormalities, caused by heterozy-
gous mutations in GNAO1. Neurological outcome is
uniformly poor in all the infants described thus far. Im-
aging may disclose indistinct brain abnormalities, such
as cerebral atrophy, delayed myelination, and/or or thin
corpus callosum.
Including the present report, twelve patients with
GNAO1 encephalopathy have been described (Table 1).
Early-onset epileptic encephalopathy has been the most
frequent presentation (n = 9), but two out of the eight
described Japanese patients, showed either few, late-
onset seizures or none at all [4]. Clinical-EEG patterns
are variable, and patients are referred to as suffering
from Ohtahara, malignant migrating partial epilepsy of
infancy, West syndrome or other forms of early epileptic
encephalopathy phenotype [2–5]. Some patients show
involuntary movements, including chorea, dystonia,
athetosis or stereotypies [2, 4].
Refractoriness to antiepileptic drugs appears a common
feature in all patients displaying the EIEE phenotype. In
our patient a complete cessation of seizures was noted
one month after the institution of a ketogenic diet and the
patient remains seizure-free five months into the diet.
Considering the widely admitted deleterious effect of
seizures on the developing brain, institution of this
therapeutic modality early in the evolution of GNAO1
encephalopathy seems advisable. Based on the loss of
calcium-current inhibition found in vitro in GNAO1
mutants, resulting from altered Gαo -mediated signal-
ing induced by norepinephrine, Nakamura et al. sug-
gested the use of selective calcium-channel blockers
or the use of the high-voltage activated calcium chan-
nels modulator topiramate to alleviate epilepsy in pa-
tients with GNAO1 mutations [2]. Our patient, at
variance with previous cases where treatment was
specified, did receive topiramate since the age of
8 months, but without noticeable improvement in sei-
zures or changes in her developmental profile.
All twelve patients described carried heterozygous de
novo missense mutations [2–5]. Indeed, the p.Leu199Pro
Fig. 4 a RMSD per residue heat-map (scale 0–15, from low/blue to high/red) for WT Gαo throughout a 1 μ-second MD simulation. b RMSD per
residue heat-map for mutant Leu199Pro Gαo. RMSD comparisons made against respective initial structures
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Table 1 Clinical features of 12 reported patients with GNAO1 encephalopathy
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is predicted to cause protein dysfunction in both of the
described GNAO1 isoforms, according to the used in
silico prediction tools. Furthermore, the application of
the recently published ACMG guidelines for interpret-
ation of sequence variants [26] to the p.Leu199Pro vari-
ant classified it as pathogenic by virtue of fulfilling one
strong (PS2) plus two moderate (PM1, PM2) and two
supporting (PP2,PP3) pathogenic criteria.
In vitro functional studies showed that three out of four
analyzed missense GNAO1 mutations resulted in abnor-
mal, cytoplasmic localization of the protein, while electro-
physiological studies proved that all four variants produced
impaired N-type calcium channel current inhibition after
norepinephrine application [2]. Interestingly, a mouse
model harboring a heterozygous (p.Gly184Ser) Gnao1 mis-
sense mutation displayed a severe and lethal epileptic
phenotype that was absent in the Gnao1 hemizygous
knock-out mouse, suggesting that pathogenic GNAO1
mutations may act through a gain-of-function, dominant
effect [27].
In our present work, we investigated the effect of the
novel p. Leu199Pro mutation in the structure of the hu-
man Gαo protein using state-of-the-art computational
tools. These provide evidence that the mutation causes
significant defects in protein stability. The observed dis-
turbances occur locally in the GTPase domain where the
mutation is situated but also in several loop regions
throughout the protein. This suggests the p.Leu199Pro
mutation decreases overall structural stability and per-
haps folding of the Gαo protein. From a functional point
of view, the location of the p.Leu199Pro mutation may
be particularly significant in terms of interactions Gαo
makes with its binding partner Gβϒ and others. With
respect to the crystal structure of the complete hetero-
trimeric guanine-nucleotide-binding protein Gi (PDB id:
1GG2), when the Gαo subunit is superimposed, the mu-
tation p.Leu199Pro is in direct contact with Gβϒ (see
Fig. 1b). Therefore any introduced structural instability
in this interface would likely adversely affect the stability
of the Gαβϒ complex as a whole. From the observed
results, it is certainly conceivable that the p.Leu199Pro
mutation could generate this level of instability. The
issue of a female gender bias in this disorder deserves
special consideration. A distorted sex ratio can be found
in many complex disorders, for instance autism spectrum
disorder [28] and a male-biased effect has been described
for 16p13.11 copy number variants as predisposing factor
to a range of neurodevelopmental disorders [29]. Possible
causes include hormonal factors, sexual dimorphic brain
differences, imprinting or genetic modifiers, with a net ef-
fect of greater protection of the female brain. It is conceiv-
able that the penetrance of GNAO1 mutation is higher
in the less resilient male brain thus producing a more se-
vere phenotype. While female bias in EIEE-17 remains
unexplained, it could be posited that disruption of G-
protein signal transduction may lead to prenatal lethality
in males.
Conclusions
We describe a further female patient with GNAO1-associ-
ated neonatal-onset epilepsy and a severe neurodevelop-
mental disorder. Seizures were amenable to treatment
with KD. Structural analysis of the novel mutation sug-
gests it introduces significant structural instability into
both the Gαo subunit and the whole G-protein heterotri-
meric complex. The resulting defective cellular signal
transduction is in all probability deleterious during brain
development and putatively fatal in the male embryo.
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Additional file 1: Table S1. Sequence alignment as calculated by
NCBI-BLAST between human Gαo (Query) and mouse Gαo (Sbjct, PDB id:
3C7K). (DOC 69 kb)
Abbreviations
ACEMD: accelerating biomolecular dynamics in the microsecond time scale;
BWA: Burrows-wheeler aligner; CGH: comparative genomic hybridization;
CSF: cerebrospinal fluid; ddG: predicted free-energy change;
EEG: electroencephalography; EEIE: early infantile epileptic encephalopathy;
GABA: gamma-aminobutyric acid; GATK: genome analysis toolkit;
GDP: guanosine diphosphate; Gi: inhibitory G-proteins; Go: “other” G-proteins;
GPCRs: G-protein coupled receptors; Gs: stimulatory G-proteins;
GTP: guanosine triphosphate; IGV: integrative genome viewer; KD: ketogenic
diet; MD: molecular dynamics; MG: magnesium; MRI: magnetic resonance
imaging; PCR: polymerase-chain-reaction; PDB: protein data bank;
RMSD: root-mean-square deviation; VQSR: variant quality score recalibration;
WT: wildtype.
Competing interests
The authors declare that they have no competing interests.
Author’s contributions
AMG carried out the molecular genetic studies and validated the findings,
JD performed the computational structural analyses, JLP provided the clinical
and neuroradiological data, MCGJ and LMG carried out metabolic studies
related to treatment and helped to draft the manuscript, ECL set up the
bioinformatic analysis pipeline, JG devised the computational approach to
mutation analysis and interpreted the data, AM conceived the study and
drafted the manuscript. All authors have read and approved the final manuscript.
Acknowledgements
This work was funded by grants from Instituto de Salud Carlos III Madrid,
Spain (PI12/01005), Ministerio de Economía y Competitividad, Spain
(SAF2014-58396-R) and AGAUR, Barcelona, Spain (SGR2009/0078); AM-G is
the recipient of a scholarship from Vall d’Hebron Institut de Recerca (Barcelona,
Spain); EC-L supported by a Beatriu de Pinós post-doctoral grant from AGAUR
(Barcelona, Spain).
The authors would like to thank the Exome Aggregation Consortium and
the groups that provided exome variant data for comparison (a full list of
contributing groups can be found at http://exac.broadinstitute.org/about)
and the NHLBI GO Exome Sequencing Project and its ongoing studies which
produced and provided exome variant calls for comparison: the Lung GO
Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924),
the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing
Project (HL-102926) and the Heart GO Sequencing Project (HL-103010).
Marcé-Grau et al. Orphanet Journal of Rare Diseases  (2016) 11:38 Page 8 of 9
Author details
1Grup de Recerca en Neurologia Pediàtrica, Vall d’Hebron Institut de Recerca,
Universitat Autònoma de Barcelona, Pg Vall d’Hebron 119-129, 08035
Barcelona, Spain. 2Laboratory of Molecular Neuropharmacology and
Bioinformatics, Institut de Neurociències and Unitat de Bioestadística,
Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
3Sección de Neuropediatría, Hospital Universitario Miguel Servet, P° Isabel la
Católica 1,3, 50009 Zaragoza, Spain. 4Sección de Metabolismo, Hospital
Universitario Miguel Servet, P° Isabel la Católica 1,3, 50009 Zaragoza, Spain.
5Secciones de Neuropediatría y Metabolismo, Hospital Universitario Miguel
Servet, P° Isabel la Católica 1,3, 50009 Zaragoza, Spain. 6Pediatric Neurology
Section, Hospital Universitari Vall d’Hebron, Pg Vall d’Hebron 119-129, 08035
Barcelona, Spain.
Received: 7 January 2016 Accepted: 16 March 2016
References
1. Dulac O. Epileptic encephalopathy. Epilepsia. 2001;42 Suppl 3:23–6.
2. Nakamura K, Kodera H, Akita T, Shiina M, Kato M, Hoshino H, et al. De novo
mutations in GNAO1, encoding a G-alpha-o subunit of heterotrimeric G
proteins, cause epileptic encephalopathy. Am J Hum Genet. 2013;93:496–505.
3. EuroEPINOMICS-RES Consortium; Epilepsy Phenome/Genome Project; Epi4K
Consortium. De novo mutations in synaptic transmission genes including
DNM1 cause epileptic encephalopathies. Am J Hum Genet. 2014;95:360–70.
4. Saitsu H, Fukai R, Ben-Zeev B, Sakai Y, Mimaki M, Okamoto N, et al.
Phenotypic spectrum of GNAO1 variants: epileptic encephalopathy to
involuntary movements with severe developmental delay. Eur J Hum
Genet. 2016;24:129–34.
5. Talvik I, Moller R, Vaher M, Vaher U, Larsen LHG, Dahl H, et al. Clinical
phenotype of De novo GNAO1 mutation: case report and review of
literature. Child Neurology Open. 2015. doi:10.1177/2329048X15583717.
6. Strathmann M, Wilkie TM, Simon MI. Alternative splicing produces
transcripts encoding two forms of the alpha subunit of GTP-binding protein
Go. Proc Natl Acad Sci U S A. 1990;87:6477–81.
7. Brown DA, Sihra TS. Presynaptic signaling by heterotrimeric G-proteins.
Handb Exp Pharmacol. 2008;184:207–60.
8. Exome Agregation Consortium, Lek M, Karczewski KJ, Minkel EV, Samocha KE,
Banks E et al. Analysis of protein-coding genetic variation in 60,706 humans.
bioRxiv preprint first posted online Oct. 30, 2015; doi: 10.1101/030338.
9. Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle,
WA (http://evs.gs.washington.edu/EVS/) (accessed January, 2016)
10. A global reference for human genetic variation, The 1000 Genomes Project
Consortium, Nature 526, 68–74 (01 October 2015) doi:10.1038/nature15393.
11. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K.
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;
29(1):308–11.
12. Sali A. Comparative protein modeling by satisfaction of spatial restraints.
Mol Med Today. 1995;1:270–7.
13. Case DA, Cheatham 3rd TE, Darden T, Gohlke H, Luo R, Merz Jr KM, et al.
The Amber biomolecular simulation programs. J Comput Chem. 2005;26:
1668–88.
14. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC,
et al. UCSF Chimera–a visualization system for exploratory research and
analysis. J Comput Chem. 2004;25:1605–12.
15. Simons KT, Kooperberg C, Huang E, Baker D. Assembly of protein tertiary
structures from fragments with similar local sequences using simulated
annealing and Bayesian scoring functions. J Mol Biol. 1997;268:209–25.
16. Kellogg EH, Leaver-Fay A, Baker D. Role of conformational sampling in
computing mutation-induced changes in protein structure and stability.
Proteins. 2011;79:830–8.
17. Harvey MJ, Giupponi G, De Fabritiis G. ACEMD: accelerating biomolecular
dynamics in the microsecond time scale. J Chem Theory Comput. 2009;5:1632–9.
18. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol
Graph. 1996;14:33–8. 27–8.
19. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional
effect of amino acid substitutions and indels. PLoS ONE. 2012;7, e46688.
20. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation
prediction for the deep-sequencing age. Nat Methods. 2014;11:361–2.
21. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
Kondrashov AS, Sunyaev SR. Nat Methods. 2010;7:248–9.
22. Smith PJ, Zhang C, Wang J, Chew SL, Zhang MQ, Krainer AR. An increased
specificity score matrix for the prediction of SF2/ASF-specific exonic splicing
enhancers. Hum Mol Genet. 2006;15:2490–508.
23. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: a web resource
to identify exonic splicing enhancers. Nucl Acids Res. 2003;31:3568–71.
24. Hebsgaard SM, Korning PG, Tolstrup N, Engelbrecht J, Rouze P, Brunak S.
Splice site prediction in Arabidopsis thaliana DNA by combining local and
global sequence information. Nucl Acids Res. 1996;24:3439–52.
25. Brunak S, Engelbrecht J, Knudsen S. Prediction of human mRNA donor and
acceptor sites from the DNA sequence. J Mol Biol. 1991;220:49–65.
26. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
guidelines for the interpretation of sequence variants: a joint consensus
recommendation of the American College of Medical Genetics and Genomics
and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.
27. Kehrl JM, Sahaya K, Dalton HM, Charbeneau RA, Kohut KT, Gilbert K, et al.
Gain-of-function mutation in Gnao1: a murine model of epileptiform
encephalopathy (EIEE17)? Mamm Genome. 2014;25:202–10.
28. Whiteley P, Todd L, Carr K, Shattock P. Gender ratios in Autism, Asperger
syndrome and Autism spectrum disorder. Autism Insights. 2010;2:17–24.
29. Tropeano M, Ahn JW, Dobson RJ, Breen G, Rucker J, Dixit A, et al. Male-biased
autosomal effect of 16p13.11 copy number variation in neurodevelopmental
disorders. PLoS One. 2013;18:e61365.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Marcé-Grau et al. Orphanet Journal of Rare Diseases  (2016) 11:38 Page 9 of 9
